Coverage
-
February 11, 2015
A New York federal judge on Tuesday rejected Teva Pharmaceuticals USA Inc.'s bid to block sales of generic versions of its multiple sclerosis drug Copaxone following a recent U.S. Supreme Court patent decision, ruling that he had no authority to grant Teva's request.
2 other articles on this case.
View all »